-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review

PUBT·05/26/2026 11:01:44
Listen to the news
Outlook Therapeutics says FDA grants appeal on Lyt​enava effectiveness in nAMD review
  • FDA granted Outlook Therapeutics’ appeal in a formal dispute resolution, finding substantial evidence of effectiveness for LYTENAVA in nAMD.
  • The company expects to resubmit its LYTENAVA BLA in June 2026.
  • The FDA indicated the filing should be a Class 1 resubmission, implying a decision within 60 days of receipt.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260700PRIMZONEFULLFEED9726100) on May 26, 2026, and is solely responsible for the information contained therein.